体外HBV感染的人肝癌Huh7细胞系中葡萄糖神经酰胺合成酶活性的变化

甘建; 杨睿; 雷程程; 杨亚婷; 闫力婷; 田爱平; 毛小荣; 王莉莉; 李俊峰

doi:10.3969/j.issn.1001-5256.2021.04.021

体外HBV感染的人肝癌Huh7细胞系中葡萄糖神经酰胺合成酶活性的变化

DOI: 10.3969/j.issn.1001-5256.2021.04.021

1.
兰州大学第一临床医学院, 兰州 730000
2.
兰州大学第一医院感染科, 兰州 730000
3.
首都医科大学第十二临床医学院, 北京 100000

基金项目:

甘肃省自然科学基金 (20JR5RA364);

兰州大学第一医院院内基金 (ldyyyn2017-17);

甘肃省高等学校科学研究项目 (2018B-009);

甘肃省卫生行业科研计划项目 (GSWSKY2018-24)

利益冲突声明：本研究不存在研究者、伦理委员会成员、受试者监护人以及与公开研究成果有关的利益冲突。

作者贡献声明：甘建、杨睿负责课题设计，资料分析，撰写论文；雷程程、杨亚婷、闫力婷、王莉莉参与临床资料收集，数据分析；田爱平、毛小荣、李俊峰负责拟定写作思路，指导撰写文章，修改论文并最后定稿。

详细信息

作者简介:
甘建(1992—)，男，在读博士，主要从事感染性疾病研究

杨睿(1997—)，男，主要从事内科疾病诊治

通信作者:
李俊峰，junfenglee@126.com

二者对本文贡献相同，同为第一作者

中图分类号: R512.62
计量
- 文章访问数: 559
- HTML全文浏览量: 144
- PDF下载量: 29
- 被引次数: 0
出版历程
- 收稿日期: 2020-09-15
- 录用日期: 2020-10-21
- 出版日期: 2021-04-20

Change in the activity of glucosylceramide synthase in human hepatoma cell line with hepatitis B virus infection in vitro

1.
The First Clinical Medical College of Lanzhou University, Lanzhou 730000, China
2.
Department of Infectious Diseases, The First Hospital of Lanzhou University, Lanzhou 730000, China
3.
The 12 th Clinical Medical College of Capital Medical University, Beijing 100000, China

摘要

摘要: 目的探索糖鞘脂代谢合成关键酶葡萄糖神经酰胺(GCS)在体外HBV感染Huh7细胞中的活性变化。方法收集2019年6月—8月就诊于兰州大学第一医院感染科的9例初治急性乙型肝炎患者的血液标本，另选7例健康体检者的血液标本作为对照。利用HBV感染者血清中高拷贝HBV颗粒(＞9.9×10⁷ IU/ml)接种Huh7细胞系(感染组)，对照组用健康体检者的血清共培养。检测HBV感染细胞胞浆中HBsAg和HBV DNA的表达量以及GCS的活性变化与病毒的相关性。计量资料多组间数据比较采用单因素方差分析，进一步两两比较采用LSD-t检验。相关性分析采用Pearson检验。结果感染组细胞较同期对照组细胞数量明显减少、细胞体积肿胀和细胞膜破碎。感染组：感染4 h、8 h、2 d和5 d后胞浆中HBsAg表达量均高于感染前(P＜0.05)；与感染4 h(16.67±11.55) IU/ml相比，感染8 h(112.01±25.94) IU/ml、2 d(328.01±103.50) IU/ml和5 d(101.60±49.84) IU/ml后胞浆中HBV DNA表达量呈明显升高趋势(P值均＜0.001)，并在感染2 d时HBV DNA表达量达到最高。在HBV感染期间，随着病毒复制的增加，GCS活性呈现出增高的特点，从感染4 h(126.21±9.59) IU/ml开始逐渐升高，并于感染2 d时(226.53±36.27) IU/ml达到高峰，感染2 d时与对照组(136.50±15.44) IU/ml比较，差异有统计学意义(t=3.956，P=0.016 7)。GCS活性与HBV DNA水平存在显著正相关(r=0.576 8, P=0.047 1)。结论 HBV感染者血清中高拷贝HBV颗粒能成功感染Huh7细胞系，并在一定程度上模拟了HBV感染的体外特点。GCS活性可能与HBV的感染有关，表明糖鞘脂合成代谢与HBV可能存在密切的联系。
- 乙型肝炎病毒 /
- 葡萄糖神经酰胺合成酶 /
- 体外培养技术
Abstract: Objective To investigate the change in the activity of glucosylceramide synthase, the key enzyme in glycosphingolipid metabolism and synthesis, in Huh7 cells infected by hepatitis B virus (HBV) in vitro. Methods Blood samples were collected from nine previously untreated patients with acute hepatitis B who attended Department of Infectious Diseases, The First Hospital of Lanzhou University, from June to August, 2019, and the blood samples collected from seven healthy individuals who underwent physical examination were established as control. Huh7 cells were inoculated with the high-copy HBV particles (> 9.9×10⁷ IU/ml) in the serum of patients with HBV infection (infection group), and Huh7 cells co-cultured with the serum of healthy individuals were established as control group. The expression levels of HBsAg and HBV DNA in the cytoplasm of HBV-infected Huh7 cells were measured, and the correlation between GCS activity and virus was analyzed. A one-way analysis of variance was used for comparison of continuous data between multiple groups, and the least significant difference t-test was used for further comparison between two groups, and a Pearson correlation analysis was performed. Results Compared with the control group, the infection group had a significant reduction in the number of cells, an increase in cell volume, and cell membrane fragmentation. The infection group had a significant increase in the expression of HBsAg in cytoplasm at 4 hours, 8 hours, 2 days, and 5 days after infection (P < 0.05); the expression level of HBV DNA tended to increase significantly from 4 hours after infection to 8 hours, 2 days, and 5 days after infection (16.67±11.55 IU/ml vs 112.01±25.94 IU/ml/328.01±103.50 IU/ml/101.60±49.84 IU/ml, P < 0.001), with the highest level at 2 days after infection. During HBV infection, the activity of GCS gradually increased with the increase in viral replication from 4 hours after infection (126.21±9.59 IU/ml) and reached a peak at 2 days after infection (226.53±36.27 IU/ml), with a significant difference between the infection group and the control group at 2 days after infection (226.53±36.27 IU/ml vs 136.50±15.44 IU/ml, t=3.956, P=0.016 7). The activity of GCS was positively correlated with HBV DNA level (r=0.576 8, P=0.047 1). Conclusion Huh7 cells are successfully infected with the high-copy HBV particles in the serum of patients with HBV infection, which mimics the characteristics of HBV infection in vitro to a certain degree. The activity of GCS may be associated with HBV infection, suggesting that glycosphingolipid synthesis and metabolism may be closely associated with HBV.
- Hepatitis B virus /
- Glucosylceramide Synthetase /
- In Vitro Techniques

HTML全文

图 1 各组细胞干预前后生长情况(×40)

下载: 全尺寸图片幻灯片

图 2 GCS活性与HBV DNA相关性

下载: 全尺寸图片幻灯片

表 1 各时间点HBV感染细胞胞浆中HBsAg和HBV DNA的表达量

时间	HBsAg(COI)	HBV DNA(IU/ml)
感染前	＜1	0
感染4 h	19.99±2.14	16.67±11.55
感染8 h	25.31±7.06	112.01±25.94
感染2 d	43.35±16.63	328.01±103.50
感染5 d	17.20±6.64	101.60±49.84
F值	9.60	18.32
P值	0.001 9	＜0.001

下载: 导出CSV

表 2 GCS在HBV感染期间的活性变化

分组	GCS(IU/ml)
对照组	136.50±15.44
感染组
感染4 h	126.21±9.59
感染8 h	167.40±23.62
感染2 d	226.53±36.27
感染5 d	108.60±17.83

下载: 导出CSV

参考文献(20)

[1]	OMATA M, KANDA T, WEI L, et al. APASL consensus statements and recommendation on treatment of hepatitis C[J]. Hepatol Int, 2016, 10(5): 702-726. DOI: 10.1007/s12072-016-9717-6.
[2]	XU ZH, LIU Y, XU DP. Advances in novel anti-HBV agents acting on different targets[J]. Infect Dis Info, 2015, 28(5): 257- 261, 283. DOI: 10.3969/j.issn.1007-8134.2015.05.001. 许智慧, 刘妍, 徐东平. 针对不同靶点的抗HBV新药研究进展[J]. 传染病信息, 2015, 28(5): 257-261, 283. DOI: 10.3969/j.issn.1007-8134.2015.05.001.
[3]	de MARTEL C, GEORGES D, BRAY F, et al. Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis[J]. Lancet Glob Health, 2020, 8(2): e180-e190. DOI: 10.1016/S2214-109X(19)30488-7.
[4]	SU Y, ZHU YF, TIAN QY, et al. In vitro cell model and mouse model of HBV cccDNA[J]. J Clin Hepatol, 2019, 35(6): 1205- 1211. DOI: 10.3969/j.issn.1001-5256.2019.06.007. 苏瑜, 朱园飞, 田青右, 等. HBV cccDNA的体外细胞模型和实验小鼠模型[J]. 临床肝胆病杂志, 2019, 35(6): 1205-1211. DOI: 10.3969/j.issn.1001-5256.2019.06.007.
[5]	NOORDEEN F, SCOUGALL CA, GROSSE A, et al. Therapeutic antiviral effect of the nucleic acid polymer REP 2055 against persistent duck hepatitis B virus infection[J]. PLoS One, 2015, 10(11): e0140909. DOI: 10.1371/journal.pone.0140909.
[6]	FLETCHER SP, CHIN DJ, GRUENBAUM L, et al. Intrahepatic transcriptional signature associated with response to interferon-α treatment in the woodchuck model of chronic hepatitis B[J]. PLoS Pathog, 2015, 11(9): e1005103. DOI: 10.1371/journal.ppat.1005103.
[7]	NI Y, LEMPP FA, MEHRLE S, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes[J]. Gastroenterology, 2014, 146(4): 1070-1083. DOI: 10.1053/j.gastro.2013.12.024.
[8]	HANNUN YA, OBEID LM. Sphingolipids and their metabolism in physiology and disease[J]. Nat Rev Mol Cell Biol, 2018, 19(3): 175-191. DOI: 10.1038/nrm.2017.107.
[9]	LIU YY, HILL RA, LI YT. Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance[J]. Adv Cancer Res, 2013, 117: 59-89. DOI: 10.1016/B978-0-12-394274-6.00003-0.
[10]	LI JF, ZHENG SJ, LIU S, et al. Impact of UGCG siRNA on 7702 hepatocyte proliferation in vitro[J]. J Pract Hepatol, 2018, 21(5): 697-700. DOI: 10.3969/j.issn.1672-5069.2018.05.011. 李俊峰, 郑素军, 刘霜, 等. 葡萄糖神经酰胺葡萄糖基转移酶siRNA对7702肝细胞增殖的影响及机制研究[J]. 实用肝脏病杂志, 2018, 21(5): 697-700. DOI: 10.3969/j.issn.1672-5069.2018.05.011.
[11]	WEGNER MS, GRUBER L, MATTJUS P, et al. The UDP-glucose ceramide glycosyltransferase (UGCG) and the link to multidrug resistance protein 1 (MDR1)[J]. BMC Cancer, 2018, 18(1): 153. DOI: 10.1186/s12885-018-4084-4.
[12]	WANG T, WEI J, WANG N, et al. The glucosylceramide synthase inhibitor PDMP sensitizes pancreatic cancer cells to MEK/ERK inhibitor AZD-6244[J]. Biochem Biophys Res Commun, 2015, 456(3): 821-826. DOI: 10.1016/j.bbrc.2014.12.019.
[13]	FAVRE D, PETIT MA, TRÉPO C. Latent hepatitis B virus (HBV) infection and HBV DNA integration is associated with further transformation of hepatoma cells in vitro[J]. ALTEX, 2003, 20(3): 131-142.
[14]	ZHONG G, YAN H, WANG H, et al. Sodium taurocholate cotransporting polypeptide mediates woolly monkey hepatitis B virus infection of Tupaia hepatocytes[J]. J Virol, 2013, 87(12): 7176-7184. DOI: 10.1128/JVI.03533-12.
[15]	CHOI BH, PARK CJ, RHO HM. Insulin activates the hepatitis B virus X gene through the activating protein-1 binding site in HepG2 cells[J]. DNA Cell Biol, 1998, 17(11): 951-956. DOI: 10.1089/dna.1998.17.951.
[16]	ZHENG SJ, QU F, LI JF, et al. Serum sphingomyelin has potential to reflect hepatic injury in chronic hepatitis B virus infection[J]. Int J Infect Dis, 2015, 33: 149-155. DOI: 10.1016/j.ijid.2015.01.020.
[17]	ZHANG JY, QU F, LI JF, et al. Up-regulation of plasma hexosylceramide (d18: 1/18: 1) contributes to genotype 2 virus replication in chronic hepatitis C: A 20-year cohort study[J]. Medicine (Baltimore), 2016, 95(23): e3773. DOI: 10.1097/MD.0000000000003773.
[18]	WERR M, PRANGE R. Role for calnexin and N-linked glycosylation in the assembly and secretion of hepatitis B virus middle envelope protein particles[J]. J Virol, 1998, 72(1): 778-782. DOI: 10.1128/JVI.72.1.778-782.1998.
[19]	XU J, ZHAO W, SUN J, et al. Novel glucosylceramide synthase inhibitor based prodrug copolymer micelles for delivery of anticancer agents[J]. J Control Release, 2018, 288: 212-226. DOI: 10.1016/j.jconrel.2018.09.011.
[20]	LEVERY SB, MOMANY M, LINDSEY R, et al. Disruption of the glucosylceramide biosynthetic pathway in Aspergillus nidulans and Aspergillus fumigatus by inhibitors of UDP-Glc: Ceramide glucosyltransferase strongly affects spore germination, cell cycle, and hyphal growth[J]. FEBS Lett, 2002, 525(1-3): 59-64. DOI: 10.1016/s0014-5793(02)03067-3.